Study of Early Intravenous Landiolol Versus Oral Beta-Blockers to Reduce Heart Damage After a Heart Attack

What this Trial Is About

Researchers are studying the effects of intravenous beta-blockers on the size of the damaged heart area after a heart attack called ST-elevation myocardial infarction STEMI. The study aims to find out if giving landiolol, a specific beta-blocker, early after the heart attack can reduce the damage compared to standard oral beta-blockers. This is an observational study enrolling patients undergoing primary angioplasty for STEMI, where treatment choice depends on the cardiologists judgment without random assignment. Patients will be grouped based on whether they receive intravenous landiolol or oral beta-blockers according to current European Society of Cardiology guidelines. The size of the heart damage will be measured by cardiac magnetic resonance imaging at least three months after the heart attack. Heart function will also be checked during hospital stay using echocardiography, including a specific measurement called global longitudinal strain. Blood tests and continuous heart rhythm monitoring will be done to assess injury markers and arrhythmia during hospitalization. Participants will undergo cardiac imaging, heart function tests, and blood sampling at scheduled times during and after hospital care. Researchers will track heart rhythm over the first 24 hours and monitor safety outcomes like shock, slow heart rate, low blood pressure, and heart failure during hospital stay up to 10 days. The main outcomes include infarct size measured by MRI after three months and heart function early after the heart attack. The total study period involves initial hospitalization and follow-up imaging months later.

Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction